Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 5/20 | 1.00 |
| ▸ | SLC6A2 | P23975 | 4/20 | 1.00 |
| ▸ | SLC6A3 | Q01959 | 4/20 | 1.00 |
| ▸ | KCNK2 | O95069 | 2/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 2/20 | 1.00 |
| ▸ | CACNA1C | Q13936 | 2/20 | 1.00 |
| ▸ | SLC7A5 | Q01650 | 7/20 | 0.82 |
| ▸ | MEN1 | O00255 | 4/20 | 0.68 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.68 |
| ▸ | LMNA | P02545 | 4/20 | 0.68 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.68 |
| ▸ | NPC1 | O15118 | 2/20 | 0.68 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.68 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.68 |
| ▸ | MTOR | P42345 | 2/20 | 0.68 |
| ▸ | RAB9A | P51151 | 2/20 | 0.68 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.68 |
| ▸ | HTR2C | P28335 | 2/20 | 0.68 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.68 |
| ▸ | TP53 | P04637 | 1/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Seproxetine SCHEMBL272873 | 1.00 | SLC6A4 (1.00) | SLC6A4SLC6A2SLC6A3KCNK2KCNH2 | |
| Norfluoxetine SCHEMBL686500 | 1.00 | SLC6A4 (1.00) | SLC6A4SLC6A2SLC6A3KCNK2KCNH2 | |
| Norfluoxetine SCHEMBL140929 | 0.98 | SLC6A4 (0.97) | SLC6A4SLC6A2SLC6A3KCNK2KCNH2 | |
| Seproxetine SCHEMBL120303 | 0.98 | SLC6A4 (0.97) | SLC6A4SLC6A2SLC6A3KCNK2KCNH2 | |
| Norfluoxetine SCHEMBL7306073 | 0.93 | SLC6A4 (0.87) | SLC6A4SLC6A2SLC6A3KCNK2KCNH2 | |
| SCHEMBL17267513 | 0.90 | SLC7A5 (1.00) | SLC6A4SLC6A2SLC6A3KCNK2KCNH2 | |
| SCHEMBL17267476 | 0.90 | SLC7A5 (1.00) | SLC6A4SLC6A2SLC6A3KCNK2KCNH2 | |
| SCHEMBL17267474 | 0.90 | SLC7A5 (1.00) | SLC6A4SLC6A2SLC6A3KCNK2KCNH2 | |
| SCHEMBL17267515 | 0.89 | SLC7A5 (1.00) | SLC6A4SLC6A2SLC6A3KCNK2KCNH2 | |
| SCHEMBL2738930 | 0.88 | SLC6A4 (0.78) | SLC6A4SLC6A2SLC6A3KCNK2KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7485754-B2 | Efficient method for preparing 3-aryloxy-3-arylpropylamines and their optical stereoisomers | APOTEX PHARMACHEM INC. (CA) | 2009-02-03 | — | — | US | claimed |
| WO-2007006132-A1 | AN EFFICIENT METHOD FOR PREPARING 3-ARYLOXY-3- ARYLPROPYLAMINES AND THEIR OPTICAL STEREOISOMERS | APOTEX PHARMACHEM INC. (CA) | 2007-01-18 | — | — | WO | claimed |
| US-20070010678-A1 | Efficient method for preparing 3-aryloxy-3-arylpropylamines and their optical stereoisomers | APOTEX PHARMACHEM INC. | 2007-01-11 | — | — | US | claimed |
| CN-119120634-A | Process for the preparation of (R) -oxiranes based on epoxide hydrolases | 杭州微远生物科技有限公司 | 2024-12-13 | — | — | CN | disclosed |
| CN-118147265-B | Chiral resolution method of oxirane compound based on epoxide hydrolase | 杭州微远生物科技有限公司 | 2024-11-05 | — | — | CN | disclosed |
| CN-118147265-A | Chiral resolution method of oxirane compound based on epoxide hydrolase | 杭州微远生物科技有限公司 | 2024-06-07 | — | — | CN | disclosed |
| CN-111944774-B | Alcohol dehydrogenase, encoding gene thereof and application of alcohol dehydrogenase in catalytic synthesis of (R) -styrene glycol | 河北大学 | 2022-05-20 | — | — | CN | disclosed |
| US-20130123253-A1 | MODULATORS OF CENTRAL NERVOUS SYSTEM NEUROTRANSMITTERS | HUMAN BIOMOLECULAR RESEARCH INSTITUTE (US) | 2013-05-16 | — | — | US | disclosed |
| US-8168635-B2 | 2-(aminomethyl)-5-phenyltetrahydrofuran; 4-(3,4-Dimethoxyphenyl)-2-[5-(2-{5-[2-(5-fluoro-2-methoxyphenyl)-ethyl]-tetrahydrofuran-2-yl}-ethylamino)-pentyl]-4a,5,8,8a-tetrahydro-2H-phthalazin-1-one; dual inhibitor of serotonin reuptake and phosphodiesterase 4 (PDE4) enzyme activity | HUMAN BIOMOLECULAR RESEARCH INSTITUTE (US) | 2012-05-01 | — | — | US | disclosed |
| US-20110136914-A1 | SUBSTITUTED ARYLOXYPROPYLAMINES WITH SEROTONINERGIC AND/OR NOREPINEPHRINERGIC ACTIVITY | AUSPEX PHARMACEUTICALS, INC. (US) | 2011-06-09 | — | — | US | disclosed |
| US-20110136914-A1 | SUBSTITUTED ARYLOXYPROPYLAMINES WITH SEROTONINERGIC AND/OR NOREPINEPHRINERGIC ACTIVITY | AUSPEX PHARMACEUTICALS, INC. (US) | 2011-06-09 | — | — | US | disclosed |
| US-20100292289-A1 | TREATMENT OF METABOLIC SYNDROME WITH NOVEL AMIDES | AMPLA PHARMACEUTICALS INC. (US) | 2010-11-18 | — | — | US | disclosed |
| US-20100292289-A1 | TREATMENT OF METABOLIC SYNDROME WITH NOVEL AMIDES | AMPLA PHARMACEUTICALS INC. (US) | 2010-11-18 | — | — | US | disclosed |
| US-20100292289-A1 | TREATMENT OF METABOLIC SYNDROME WITH NOVEL AMIDES | AMPLA PHARMACEUTICALS INC. (US) | 2010-11-18 | — | — | US | disclosed |
| US-20080261967-A1 | Modulators of Central Nervous System Neurotransmitters | HUMAN BIOMOLECULAR RESEARCH INSTITUTE | 2008-10-23 | — | — | US | disclosed |
| US-20070155820-A1 | SUBSTITUTED ARYLOXYPROPYLAMINES WITH SEROTONINERGIC AND/OR NOREPINEPHRINERGIC ACTIVITY | AUSPEX PHARMACEUTICALS, INC. (US) | 2007-07-05 | — | — | US | disclosed |
| US-20070155820-A1 | SUBSTITUTED ARYLOXYPROPYLAMINES WITH SEROTONINERGIC AND/OR NOREPINEPHRINERGIC ACTIVITY | AUSPEX PHARMACEUTICALS, INC. (US) | 2007-07-05 | — | — | US | disclosed |
| WO-2007062119-A1 | SUBSTITUTED ARYLOXYPROPYLAMINES WITH SEROTONINERGIC AND/OR NOREPINEPHRINERGIC ACTIVITY | AUSPEX PHARMACEUTICALS, INC. (US) | 2007-05-31 | — | — | WO | disclosed |
| US-20070078188-A1 | Compositions comprising and methods of using norfluoxetine | CURRIE MARK G | 2007-04-05 | — | — | US | disclosed |
| US-20070078188-A1 | Compositions comprising and methods of using norfluoxetine | CURRIE MARK G | 2007-04-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110136914-A1 | SUBSTITUTED ARYLOXYPROPYLAMINES WITH SEROTONINERGIC AND/OR NOREPINEPHRINERGIC ACTIVITY | SLC6A4, HTR4, GPR34 | SLC6A4 1/4885SLC6A2 5/4885SLC6A3 17/4885 |
| US-20080261967-A1 | Modulators of Central Nervous System Neurotransmitters | GAP43, SLC18A2, CHRNA6 | SLC6A4 104/4885SLC6A2 47/4885SLC6A3 54/4885 |
| US-20070155820-A1 | SUBSTITUTED ARYLOXYPROPYLAMINES WITH SEROTONINERGIC AND/OR NOREPINEPHRINERGIC ACTIVITY | SLC6A4, HTR4, GPR34 | SLC6A4 1/4885SLC6A2 5/4885SLC6A3 17/4885 |
| US-20070010678-A1 | Efficient method for preparing 3-aryloxy-3-arylpropylamines and their optical stereoisomers | SLC6A4, HTR3A, TPH2 | SLC6A4 1/4885SLC6A2 13/4885SLC6A3 12/4885 |
| US-20130123253-A1 | MODULATORS OF CENTRAL NERVOUS SYSTEM NEUROTRANSMITTERS | GAP43, SLC18A2, CHRNA6 | SLC6A4 104/4885SLC6A2 47/4885SLC6A3 54/4885 |
| US-20100292289-A1 | TREATMENT OF METABOLIC SYNDROME WITH NOVEL AMIDES | GPR119, CPT1A, GLS2 | SLC6A4 1007/4885SLC6A2 962/4885SLC6A3 2178/4885 |
| US-20070078188-A1 | Compositions comprising and methods of using norfluoxetine | ALOX5, NGF, PTGER4 | SLC6A4 36/4885SLC6A2 70/4885SLC6A3 292/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.